A Point Biopharma Global cancer therapy key to a $1.4 billion Eli Lilly M&A deal has met the main goal of its pivotal clinical trial in prostate cancer. But the results raise questions about how well ...
BEDFORD, Mass., and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- December 18, 2023 – Lantheus Holdings, Inc. (LNTH) (Lantheus) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced ...
There have been renewed calls for the introduction of a national screening programme for prostate cancer in the UK. Former British prime minister Rishi Sunak, actors and sportspeople have joined a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results